[img]https://investorshub.advfn.com/uimage/uploads/2018/12/31/hhrise540defe.jpg[/img]
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well thats a juicy nugget isnt it?
Happy Friday!
Like GW always says---"In Time"
nxttf
Thank you for all of your insight over the years. It is always a breathe of fresh air.
GL
NXTTF
I picked up ~13k at around .07 yesterday
GL
NXTTF
YEP. its going to be a fun few months/years
GL
VFF
Not from this company.
I am not in this POS and havent been for years. Thank God.
This toilet bowl is swirling.
This company is gasping
Solid advice. I have shares in the 2's and I am adding here
Absolutely! Good to see ya Pisd!
Go Village!
VFF
Yep. it will be fun to watch the scramble for shares
VFF
Looks like they are killing it.
VFF
Over a million on the ask??
This what happens when you have press release mentioning Emerald. LOL!!!
I have been quietly loading up all summer. It is going to be awesome. SOOOOOO undervalued right now
No kidding!
I have begun accumulating. See you at a higher SP
This board just keeps getting classier by the day
Earnings after hours today?
Anyone from the "old days" watching this???
I am. Which is now a fraction of the money that was actually invested. That loss Hass to be offset somewhere and it’s usually against games for the year. Which obviously doesn’t allow you to put as much profits in your pocket.
I guess the theory makes sense if you are thinking they are going to go bankrupt but otherwise average down and get out as soon as you can at break even.
I guess my point was that doesn’t make sense to sell down here with the intent of buying lower later.
I hope everybody makes money, I just didn’t understand that thinking
GLTA
That is not true. Tax loss selling takes away from gains.
It’s a wash at best
Why would one sell for a loss and then “get back in”?
Why not average down and leverage the low price to get you to a place that allows you to not realize the initial loss?
IMO the only time you sell for a loss is to offset capital gains. But, if this is the only stocks you invest in, you don’t have that option. Diversification is key
And- if you “know” it is going “down down down until Q3”, why not take that info to hedge against potential losses (high cost lots)
I guess to each their own but I dont understand the thinking
Probably better sell the rest of your shares if that is the case eh?
Starting to smell a bit toasty in here
Didn’t you sell all your shares? I notice all of your posts are negative so are you just trying to inform people or what is the deal?
SAN DIEGO, CA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet need, has successfully completed genotoxicity studies of THCVHS required prior to beginning its planned Phase 1 clinical study in Australia. Skye is initially developing THCVHS as a treatment of glaucoma.
Genotoxicity safety studies are required by both the Australian Therapeutic Goods Administration and the U.S. Food & Drug Administration prior to initiating human trials and were completed at BioReliance Corporation under Good Laboratory Practices regulations, which meet the standards for both agencies. BioReliance is the world’s leading provider of safety testing services and includes among its customers many of the largest pharmaceutical, biopharmaceutical, and chemical companies around the globe.
“Genotoxicity data are a prerequisite to enter into human trials in all major markets. Although the safety profile for the active pharmaceutical ingredient, THC, is well-recognized, this was the first time these studies were performed with our proprietary molecule THCVHS, a prodrug of THC,” said Punit Dhillon, CEO of Skye Bioscience. “We are pleased to have successfully completed these studies and continue to advance our nonclinical requirements prior to initiating our first-in-human trial, as well as future clinical trials in the US.”
Two studies were carried out to assess the genotoxicity potential of THCVHS. The first was a mammalian cell micronucleus assay, which is designed to determine a compound’s ability to generate chromosomal aberrations and considered to be one of the most reliable assays in determining genotoxicity. The second study was a reverse bacterial mutagenesis assay, also referred to as the Ames test, which assesses the ability of a compound to generate gene mutations. Both assays produced negative results indicating that THCVHS is not a genotoxic compound, clearing a key step to allow for human trials.
About THCVHS
THCVHS, a proprietary prodrug of tetrahydrocannabinol (THC), is a topical formulation under development to treat glaucoma. Through the application of rational drug design, Skye has chemically modified THC to create a unique synthetic molecule with the intent to safely realize the known positive effects of THC. THCVHS enables enhanced local delivery of the drug into the eye, provides significant lowering of intraocular pressure, minimal systemic exposure, and potential for neuroprotection.
About Skye Bioscience
Skye Bioscience Inc. is a biopharmaceutical company unlocking the pharmaceutical potential of cannabinoids through the development of its proprietary, cannabinoid-derived molecules to treat diseases with significant unmet needs. The company’s lead program, THCVHS, is focused on treating glaucoma, a disease with no cure and the world’s leading cause of irreversible blindness. For more information, please visit: www.skyebioscience.com.
BZ: UPDATE: Craig-Hallum Says Village Farms Has 'Best-In-Class Organic Growth, Profitability & US Optionality'
Did anyone pick up that Canopy lost market share???
I think I know where that went.
BTW- We have 3 out of the 5 top selling flower and #1 best seller overall.
Add now vapes are to market.
Monday will be fun.
Go VVF
Run into earnings? Get them before Monday!!!!
True. And Covid resurgence might make it even weaker but those were all happy to be taken into consideration and decisions made. I think if one takes in to account The strides that should be made with those sayings factored in, you can still make an educated decision.
I definitely will not be going in heavy until Q3 verifies continued improvement
Good luck on your other plays. A lot of opportunities out there right now
So you waited all this time and sell once all the pieces are in place? Must not have time to see it play out which I totally get. Q3 is going to show a significant increase and Q4 will be explosive. IMO. But I got in Knowing it was going to be a couple year play.
GL Agreg
It wasn't blow out earnings but there is progress and staging for the real revenue explosion. IMO
The infrastructure MUST be correct before scaling and I think they took the time to do that.
Most of the skus and all off labs sales are not on this ER. They most definitely will be next Q. IMO- Q3 is the real measuring quarter because it will be the first quarter with everything in place.
I am happy with it and will be accumulating.
GL Dude!
Good luck guessing this sector about any news but honestly, I don’t think it should fall at all.
If the financials were bad, I was going to tax loss sell namaste
I don’t think they were bad therefore I will accumulate. With labs operating and to market, I expect a good jump in Q3 and an even bigger jump in Q4
GLTA
I’m stoked. Just hard to say anything without ppl freaking out no matter what you say.
This ER was exactly what I needed to see in order to start heavily averaging down with confidence.
agreed
Namaste Technologies Reports Second Quarter 2021 Financial Results
Three Consecutive Quarters of Improved Gross Margins
Cannabis Revenue Increased by 18% in Q2 2021 Compared to Q2 2020
EBITDA Improvements in All Operating Segments
TORONTO, July 29, 2021 (GLOBE NEWSWIRE) -- Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) a marketplace platform for cannabis and wellness products, today reported its financial results for the second quarter ended May 31, 2021 (“Q2 2021”) with references made to financial results for the second quarter ended May 31, 2020 (“Q2 2020”). All financial figures are in Canadian dollars unless otherwise indicated.
Q2 2021 Highlights:
Three consecutive quarters of improved gross margins before inventory adjustments as a result of increased sales of higher margin products.
Gross revenue for Q2 2021 was $6.3 million, of which a strong 52% is attributable to cannabis revenues, with cannabis revenues growing 18% in Q2 2021 compared to Q2 2020.
Operating expenses for the six-month period decreased by 15% compared to the same period in 2020 and contributed to improved EBITDA in all operating segments. Overall EBITDA across operating segments improved 33% in Q2 2021 and 30% in Q2 YTD 2021.
Inventories decreased by 14% to $5.2 million in Q2 2021 ($6.0 million in the first quarter ended February 28, 2021) demonstrating continued improved inventory management practices.
The Company’s working capital position remains strong at $25 million as at May 31, 2021.
Recent Corporate Highlights:
The Company’s wholly owned subsidiary CannMart Inc. (“CannMart”), received a Health Canada renewal of its standard licence for processing and sale of cannabis under the applicable regulations.
CannMart entered into a number of supply agreements including with CannTx Life Sciences Inc. (CannMart exclusive distributor on a SKU-by-SKU basis), Rilaxe Canna Inc. (CannMart exclusive distributor) and Safari Flower Co. to expand its product offering to both its provincial cannabis board buyers and its own medical customers across Canada at CannMart.com.
The Company’s wholly owned subsidiary CannMart Labs Inc., (“CannMart Labs”) submitted its application for a Health Canada Controlled Drugs and Substances Dealer’s Licence for future storage and distribution of the following controlled substances: psilocybin, psilocin, ketamine, LSD, DMT and MDMA.
As part of our sustainability initiative, the Company successfully subleased its Toronto office location until expiry of its lease on October 30, 2024, confirming its commitment to finding top talent all over the world. The decision made by the Company is an initial step towards a long-term commitment to developing an Environment, Social and Governance (ESG) plan for meaningful action to protect our planet.
The Company’s wholly owned Swedish subsidiary Findify AB, achieved its best ever consecutive four months of sales in the first six calendar months of 2021 with revenue per new customer up 54% and subscription sales value up 106% compared to the same period last year.
CannMart, signed a Master Distribution Agreement with Rapid Dose Therapeutics Corp. (“RDT”) to be the exclusive distributor of their innovative RDT branded products across Canada.
CannMart Labs in-house brand “Roilty” received its first purchase orders from the provinces of Manitoba and Saskatechewan for its consumer-focused cannabis concentrates.
SKU listings at CannMart.com increased 589% to over 800 as of the end of Q2 2021, compared to 116 in Q1 2021 as CannMart received a record amount of requests from vendors across North America to list their products onto the CannMart.com platform.
“We are very pleased with the accomplishments we have made on the operating front which include increased margins over the last three quarters as well as an improvement in EBITDA within all our operating segments,” said Meni Morim, CEO of Namaste. “While this is important, revenues were not where we wanted them to be as Covid-19 continued to have an impact on retail establishments. However, with the reduction of Covid-19 restrictions enabling greater access to retail stores, Covid-19 will have less of an impact on future revenues combined with the continuously improving margins will have a synergistic effect on our financials moving forward. In addition, we believe our various initiatives, including the impending launch of CannMart Labs, our in-house “Roilty” shatter brand hitting the shelves in the coming months, the upcoming launch of our nutraceuticals business in Q4 2021 as well as continuing to increase the number of SKUs available at CannMart.com will contribute to sales growth and improved margins over the next few quarters. We continue to be focused on controlling our operating expenses, improving gross margins and selling the right product mix to position Namaste on a clear path and trajectory towards profitability.”
For further details, the complete Financial Statements for the second quarter ended May 31, 2021 and the related Management’s Discussion & Analysis can be accessed on the Company’s SEDAR profile at www.sedar.com.
NON IFRS FINANCIAL MEASURES
Management evaluates the Company’s performance using a variety of measures, including “Net loss before income tax, depreciation and amortization” and “Adjusted EBITDA”. The non-IFRS measures discussed below should not be considered as an alternative to or to be more meaningful than revenue or net loss. These measures do not have a standardized meaning prescribed by IFRS and therefore they may not be comparable to similarly titled measures presented by other publicly traded companies and should not be construed as an alternative to other financial measures determined in accordance with IFRS.
The Company believes these non-IFRS financial measures provide useful information to both management and investors in measuring the financial performance and financial condition of the Company.
Management uses these and other non-IFRS financial measures to exclude the impact of certain expenses and income that must be recognized under IFRS when analyzing consolidated underlying operating performance, as the excluded items are not necessarily reflective of the Company’s underlying operating performance and make comparisons of underlying financial performance between periods difficult. From time to time, the Company may exclude additional items if it believes doing so would result in a more effective analysis of underlying operating performance. The exclusion of certain items does not imply that they are non-recurring.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f2b450d6-f2b5-496b-a252-51ee1ccab229
(i) Current and deferred income taxes, depreciation and amortization, and share-based compensation were excluded from the Adjusted EBITDA calculation as they do not represent cash expenditures.
(ii) Other income consisting of gain on disposal of subsidiary, interest income, realized gain on disposition of AFS investments, unrealized gain on derivatives and other miscellaneous non-recurring income were excluded from Adjusted EBITDA calculation.
(iii) Non-recurring costs related to restructuring and legacy issues were excluded from Adjusted EBITDA calculation.
(iv) Impairment loss relating to goodwill, customer list, domains and brand names were excluded from Adjusted EBITDA calculation.
(v) Impairment loss relating to receivable is a provision for expected credit loss to an associate and was excluded from Adjusted EBITDA calculation.
(vi) Share of associates loss, net of tax, is excluded due to lack of control.
About Namaste Technologies Inc.
Namaste Technologies is a marketplace platform for cannabis and wellness products. At CannMart.com, the Company provides Canadian medical customers with a diverse selection of hand-picked products from a multitude of federally licensed cultivators and US customers with access to hemp-derived CBD and smoking accessories. The Company also distributes licensed and in-house branded cannabis and cannabis derived products in Canada through a number of provincial government control boards and retailing bodies and facilitates licensed cannabis retailer sales online in Saskatchewan. Namaste’s global technology and continuous innovation address local needs in a burgeoning cannabis industry requiring smart solutions.
Information on the Company and its many products can be accessed through the links below:
NamasteTechnologies.com
NamasteMD.com
Cannmart.com
For more information please contact:
Namaste Technologies Inc.
Meni Morim, CEO
Edward Miller, VP Investor Relations
Ph: 647-362-0390
Email: ir@namastetechnologies.com
Source: Namaste Technologies Inc
FORWARD-LOOKING INFORMATION – This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as “may”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen.
The forward-looking information contained herein, including, without limitation, statements related to the Company’s expectations relating to increasing top line revenue, its intended adjustment to its product mix, the Company’s expected launch of new products and the creation of its new nutraceutical division, the Company’s continued focus on improving margins toward its goal to be profitable, are made as of the date of this press release and are based on assumptions management believed to be reasonable at the time such statements were made, including, without limitation, Namaste’s ability to maintain momentum of expanding its business, its ability to broaden its total addressable market and to evolve into a recognized wellness company, the Company’s expectation that the nutraceutical and wellness market and potentially the market for psychedelics will develop as currently anticipated, the nutraceutical market will continue to be a multi-billion dollar high-margin market, the introduction of new products and brands will generate additional revenue, the ability of the Company to turn inventory as anticipated, the impact and duration of covid-19 lockdowns on the business of the Company diminishing in the future, as well as other considerations that are believed to be appropriate in the circumstances. While the Company considers these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation: the inability of the Company to develop its business as anticipated and to increase revenues and/or its profitable margin on such revenues, unanticipated changes to current regulations that would adversely impact the Company’s business and proposed business and other regulatory risks, risks relating to the Company’s ability to execute its business strategy and the benefits realizable therefrom and risks specifically related to the Company’s operations. Additional risk factors can also be found in the Company’s current MD&A and annual information form, both of which have been filed under the Company’s SEDAR profile at www.sedar.com. Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.
So that means that labs is not only up and running but has product available to sell.
Am I reading that right? If that is the case, execution is happening. Big Time